trial summary · NCT07803952
N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis
Adjunctive N-Acetylcysteine in the Management of Spontaneous Bacterial Peritonitis in Patients With Liver Cirrhosis: A Randomized Controlled Trial
Trial record from the TrialBase DB dataset, status RECRUITING, condition SBP - Spontaneous Bacterial Peritonitis, sponsored by Tanta University. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Spontaneous bacterial peritonitis (SBP) is one of the most serious infectious complications of liver cirrhosis and ascites. It affects approximately 10-30% of hospitalized patients with decompensated cirrhosis and carries an in-hospital mortality of 20-40% despite appropriate antimicrobial therapy. SBP results from bacterial translocation across the intestinal mucosa together with cirrhosis-associated immune dysfunction, leading to impaired bacterial clearance and exaggerated systemic inflammation. Current international guidelines recommend immediate empirical antibiotic therapy together with intravenous human albumin to reduce the incidence of acute kidney injury (AKI), hepatorenal syndrome, and mortality. Although this strategy has substantially improved outcomes, treatment failure, persistent infection, renal dysfunction, acute-on-chronic liver failure (ACLF), and early mortality remain common, indicating that currently available therapy does not adequately address all pathogenic mechanisms of SBP. Increasing evidence suggests that oxidative stress is a central contributor to the progression of bacterial infections in cirrhosis. Excessive production of reactive oxygen species aggravates hepatocellular injury, endothelial dysfunction, immune dysregulation, and renal impairment, thereby amplifying systemic inflammatory responses during SBP. Consequently, therapeutic strategies targeting oxidative stress may improve host defense while limiting organ injury. N-acetylcysteine (NAC) is a precursor of glutathione and one of the most extensively studied antioxidant agents in …
Source record: https://clinicaltrials.gov/study/NCT07803952
Facts
| registry id | NCT07803952 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1/PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | SBP - Spontaneous Bacterial Peritonitis |
| sponsor | Tanta University |
| sponsor class | OTHER |
| enrollment | 60 |
| start date | 2026-10-25 |
| primary completion | 2027-06-01 |
| completion | 2027-06-01 |
| results posted | not reported |
Conditions
- SBP - Spontaneous Bacterial Peritonitis
Interventions
- Placebo
- NAC
Countries
- Egypt
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.